drugset / Trial / NCT05444569
A Study of LY3537021 in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.
Timeline
- Start
- 2022-08-08
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3537021 | Unknown | — | Subcutaneous |
| Background | Liraglutide | Peptide | — | Subcutaneous |
Indications
No indication recorded.